sprite-preloader
Anzeige
Mehr »
Samstag, 16.12.2017 Börsentäglich über 12.000 News von 575 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1JS1K ISIN: IE00B4Q5ZN47 Ticker-Symbol: J7Z 
Aktie:
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
JAZZ PHARMACEUTICALS PLC Chart 1 Jahr
1-Woche-Intraday-Chart
JAZZ PHARMACEUTICALS PLC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
114,27
116,23
12:00
115,01
115,54
15.12.
07.12.2017 | 22:06
(4 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

DUBLIN, Dec. 7, 2017 /PRNewswire/ --Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the BMO Capital Markets Healthcare Conference in New York, NY.

Matt Young, executive vice president and chief financial officer, will provide an overview of the company and a business and financial update at the conference on Thursday, December 14, 2017 at 10:30 a.m. EST / 3:30 p.m. GMT.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem(sodium oxybate) oral solution, Erwinaze(asparaginase Erwinia chrysanthemi), Defitelio(defibrotide sodium) and Vyxeos' (daunorubicin and cytarabine) liposome for injection inthe U.S. and markets Erwinaseand Defitelio(defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.

Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg

Jazz Pharmaceuticals Logo


© 2017 PR Newswire